Fullscript Accelerates Growth with Expanded Investment from HGGC and Snapdragon; Leonard Green & Partners Backs New Phase Through Continuation Vehicle
Article content
OTTAWA, Ontario — Fullscript, a leading healthcare platform powering whole person care, today announced an expanded investment from HGGC, a leading middle-market private equity firm, and Snapdragon Capital Partners ('Snapdragon') to support its next phase of growth. The new capital, supported by a continuation vehicle led by Leonard Green & Partners as the sole lead investor, underscores strong investor confidence in Fullscript's innovative model and long-term market leadership. HGGC, with Snapdragon as a minority investor, originally invested in Fullscript in 2021.
Article content
Article content
Founded in 2011, Fullscript has redefined whole person care by empowering healthcare providers with evidence-based supplement prescribing and fulfillment, advanced lab management capabilities and intuitive tools for improved patient adherence and outcomes. Today, Fullscript supports over 100,000 providers and 10 million patients, driving adoption of a more comprehensive and preventative approach to health.
Article content
'Fullscript is transforming how care is delivered by bridging the gap between providers and patients with a truly whole-person approach,' said Kyle Braatz, Co-Founder and CEO of Fullscript. 'This investment allows us to continue advancing our technology, expanding our services, and empowering more practitioners to deliver personalized, proactive care.'
Article content
'This transaction reflects our strong conviction in the long-term value creation potential of Fullscript, our continued belief in the vision and capability of Fullscript leadership, and the strength of our partnership with HGGC,' said Mark Grabowski, Founder and Managing Partner at Snapdragon Capital Partners. 'The continuation vehicle investment by LGP provides the flexibility to provide liquidity options to our investors and capital to support the next phase of growth while maintaining alignment across all stakeholders.'
Article content
David Fox and Garrett Hall, Co-Heads of LGP's Sage strategy, said, 'We are thrilled to partner with Snapdragon, HGGC and the leadership team at Fullscript to support their continued success. This transaction underscores our commitment to investing in high-quality, market-leading companies with strong competitive positions and sustainable long-term growth.'
Article content
HGGC is a values-driven, partnership-focused private investment firm. The firm's ecosystem of investors, operators, and professionals are united by the shared mission to develop leading enterprises and build long term value together. HGGC invests in technology, business services, financial services and consumer enterprises generally valued between $200M – $1.5B+. The firm is based in Palo Alto, CA and manages over $8 billion in cumulative capital commitments. More information, including a complete list of current and former investments, is available at www.hggc.com.
Article content
Founded in 2018, Snapdragon Capital Partners is a growth equity and buyout firm purpose-built for ambitious growth companies that are cherished by the modern consumer. The firm has a distinguished reputation in consumer services, including franchising, and a track-record of success identifying defensible growth opportunities in products and enablement technologies or B2B2C platforms. The Snapdragon portfolio includes Xponential Fitness (NYSE: XPOF), Fullscript, the Better Being Company, Fortis Franchise Group, Spartan Fitness Holdings, and JECT.
Article content
LGP is a leading private equity investment firm founded in 1989 and based in Los Angeles, California with $75 billion of assets under management. The firm partners with experienced management teams and often with founders to invest in market-leading companies. Since inception, LGP has completed over 150 investments in the form of traditional buyouts, going-private transactions, recapitalizations, growth equity, and selective public equity and debt positions. The firm primarily focuses on companies providing services, including consumer, healthcare and business services, as well as distribution and industrials. For more information, please visit www.leonardgreen.com.
Article content
Founded in 2011, Fullscript is a leading healthcare platform powering whole person care. With a full suite of clinical tools that make it easier for practices to deliver personalized care more efficiently and effectively – Fullscript has helped over 100,000 providers and 10 million patients with seamless access to high-quality supplements, industry-leading labs, and smart adherence tools.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Fullscript
Jen Newman
jen.newman@fullscript.com
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
05-05-2025
- National Post
Fullscript Accelerates Growth with Expanded Investment from HGGC and Snapdragon; Leonard Green & Partners Backs New Phase Through Continuation Vehicle
Article content OTTAWA, Ontario — Fullscript, a leading healthcare platform powering whole person care, today announced an expanded investment from HGGC, a leading middle-market private equity firm, and Snapdragon Capital Partners ('Snapdragon') to support its next phase of growth. The new capital, supported by a continuation vehicle led by Leonard Green & Partners as the sole lead investor, underscores strong investor confidence in Fullscript's innovative model and long-term market leadership. HGGC, with Snapdragon as a minority investor, originally invested in Fullscript in 2021. Article content Article content Founded in 2011, Fullscript has redefined whole person care by empowering healthcare providers with evidence-based supplement prescribing and fulfillment, advanced lab management capabilities and intuitive tools for improved patient adherence and outcomes. Today, Fullscript supports over 100,000 providers and 10 million patients, driving adoption of a more comprehensive and preventative approach to health. Article content 'Fullscript is transforming how care is delivered by bridging the gap between providers and patients with a truly whole-person approach,' said Kyle Braatz, Co-Founder and CEO of Fullscript. 'This investment allows us to continue advancing our technology, expanding our services, and empowering more practitioners to deliver personalized, proactive care.' Article content 'This transaction reflects our strong conviction in the long-term value creation potential of Fullscript, our continued belief in the vision and capability of Fullscript leadership, and the strength of our partnership with HGGC,' said Mark Grabowski, Founder and Managing Partner at Snapdragon Capital Partners. 'The continuation vehicle investment by LGP provides the flexibility to provide liquidity options to our investors and capital to support the next phase of growth while maintaining alignment across all stakeholders.' Article content David Fox and Garrett Hall, Co-Heads of LGP's Sage strategy, said, 'We are thrilled to partner with Snapdragon, HGGC and the leadership team at Fullscript to support their continued success. This transaction underscores our commitment to investing in high-quality, market-leading companies with strong competitive positions and sustainable long-term growth.' Article content HGGC is a values-driven, partnership-focused private investment firm. The firm's ecosystem of investors, operators, and professionals are united by the shared mission to develop leading enterprises and build long term value together. HGGC invests in technology, business services, financial services and consumer enterprises generally valued between $200M – $1.5B+. The firm is based in Palo Alto, CA and manages over $8 billion in cumulative capital commitments. More information, including a complete list of current and former investments, is available at Article content Founded in 2018, Snapdragon Capital Partners is a growth equity and buyout firm purpose-built for ambitious growth companies that are cherished by the modern consumer. The firm has a distinguished reputation in consumer services, including franchising, and a track-record of success identifying defensible growth opportunities in products and enablement technologies or B2B2C platforms. The Snapdragon portfolio includes Xponential Fitness (NYSE: XPOF), Fullscript, the Better Being Company, Fortis Franchise Group, Spartan Fitness Holdings, and JECT. Article content LGP is a leading private equity investment firm founded in 1989 and based in Los Angeles, California with $75 billion of assets under management. The firm partners with experienced management teams and often with founders to invest in market-leading companies. Since inception, LGP has completed over 150 investments in the form of traditional buyouts, going-private transactions, recapitalizations, growth equity, and selective public equity and debt positions. The firm primarily focuses on companies providing services, including consumer, healthcare and business services, as well as distribution and industrials. For more information, please visit Article content Founded in 2011, Fullscript is a leading healthcare platform powering whole person care. With a full suite of clinical tools that make it easier for practices to deliver personalized care more efficiently and effectively – Fullscript has helped over 100,000 providers and 10 million patients with seamless access to high-quality supplements, industry-leading labs, and smart adherence tools. Article content Article content Article content Article content Article content Contacts Article content Fullscript Jen Newman Article content Article content Article content
National Post
01-05-2025
- National Post
Tetra Tech to Advance Its Digital Automation Solutions with the Acquisition of SAGE Group
Article content PASADENA, Calif. — Tetra Tech, Inc. (NASDAQ: TTEK), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today that it has signed a definitive agreement to acquire SAGE Group Holdings Ltd (SAGE Group), a premier automation solutions provider known for its expertise in municipal water and industrial manufacturing automation, smart infrastructure, and systems integration. Article content Article content SAGE Group delivers innovative technology and high-quality automation services that optimize operational efficiency and drive digital transformation for commercial and government clients across the municipal water, energy, transportation, defense and manufacturing sectors. This acquisition will expand Tetra Tech's digital systems solutions to a broader suite of clients, and provide advanced electrical and instrumentation design, engineered control systems, cybersecurity, and cloud integration. Article content 'Tetra Tech's deep technical expertise and advanced technology solutions help utilities, and the private sector optimize performance and make effective, data-driven decisions,' said Dan Batrack, Tetra Tech Chairman and CEO. 'The addition of SAGE Group's digital automation capabilities will further enhance our offerings by bringing additional expertise, AI-enabled technology, and demonstrated client solutions to our collective team.' Article content 'Tetra Tech and SAGE Group share complementary expertise, a strong cultural fit, and a shared long-term strategic vision to deliver impactful, future-focused solutions across industrial digitalization, AI and cybersecurity,' said Adrian Fahey, SAGE Group's Managing Director. 'This partnership will position SAGE for long-term growth, broaden its service offering, and provide new global resources — enhancing the value, innovation, and support we deliver to our clients and, expanded opportunities for our employees.' Article content SAGE Group is joining the Commercial International Business Group. The acquisition will be subject to the satisfaction of customary closing conditions. Article content Tetra Tech is the leader in water, environment and sustainable infrastructure, providing high-end consulting and engineering services for projects worldwide. With 30,000 employees working together, Tetra Tech provides clear solutions to complex problems by Leading with Science ® to address the entire water cycle, protect and restore the environment, design sustainable and resilient infrastructure, and support the clean energy transition. For more information about Tetra Tech, please visit or follow us on LinkedIn and Facebook. Article content SAGE Group comprises four specialist offerings, SAGE Automation, Nukon, Embedded Expertise and Skills Lab. With an extensive footprint across Australia, employing a team of 800 talented people, SAGE is an integrated industrial digitalization services provider with a suite of solutions designed to support clients to accelerate their digital journey. SAGE partners with clients across the water, defense, energy, manufacturing, resources and transport sectors, to create a Smarter Future, Better World. For more information about SAGE Group, please visit or follow us on LinkedIn and Facebook. Article content Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgment as to what may occur in the future. However, Tetra Tech's actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions ('Future Factors'), and may differ materially from what is expressed. For a description of Future Factors that could cause actual results to differ materially from such forward-looking statements, see the discussion under the section 'Risk Factors' included in the Company's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission. Article content Article content Article content Article content Article content
Globe and Mail
19-12-2024
- Globe and Mail
Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight
DelveInsight's " Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Explore the intricate details of the Postpartum Depression Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Postpartum Depression Market Forecast. Click here to stay ahead in healthcare innovation @ Postpartum Depression Market Size Key Takeaways from the Postpartum Depression Market Research Report Among the seven major countries, the total Postpartum Depression diagnosed prevalence cases were ~1,310,000, in 2023. In EU4 and the UK, the total Postpartum Depression diagnosed prevalence cases were ~4,60,000 in 2023. In the seven major market, the United States accounted for the highest number of Postpartum Depression diagnosed cases (~720,000), followed by the UK, in 2023. In Japan, the total Postpartum Depression diagnosed prevalent cases were ~126,000 in 2023. The leading Postpartum Depression Companies such as Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others. Promising Postpartum Depression Pipeline Therapies such as SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others. Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook • Total Postpartum Depression Diagnosed Prevalent Population of Maternal Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Prevalence Postpartum Depression Marketed Therapies Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing. ZULRESSO: Sage Therapeutics ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults. The mechanism of action of brexanolone in treating PPD in adults is related to its positive allosteric modulation of GABAA receptors. Brexanolone potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing α1β2γ2 receptor subunits, α4β3δ receptor subunits, and α6β3δ receptor subunits. Postpartum Depression Emerging Therapies Ganaxolone: Marinus Pharmaceuticals Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone. Unlock insights into the Postpartum Depression Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Postpartum Depression Market Forecast. Click here @ Postpartum Depression Market Drivers and Barriers Postpartum Depression Market Outlook Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life. Scope of the Postpartum Depression Market Report Coverage- 7MM Study Period- 2020-2034 Postpartum Depression Companies- Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others. Postpartum Depression Pipeline Therapies- SAGE-217/BIIB-125, Ganaxolone, LPCN 1154, BRII-296, and others. Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers Postpartum Depression Market Access and Reimbursement, and Unmet Needs Gain a strategic edge in the Postpartum Depression Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Postpartum Depression Market Forecast. Click here to lead in advancements @ Postpartum Depression Clinical Trials Assessment Table of Content 1. Key Insights 2. Report Introduction 3. Postpartum Depression Market Overview at a Glance 4. Executive Summary of Postpartum depression (PPD) 5. Key events 6. Disease Background and Overview 7. Treatment and Management 8. Methodology 9. Epidemiology and Patient Population 10. Patient Journey 11. Marketed Therapies 12. Emerging Therapies 13. Postpartum Depression (PPD): Seven Major Market Analysis 14. KOL Views 15. SWOT Analysis 16. Unmet Needs 17. Market Access and Reimbursement 18. Appendix 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
